Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Ocugen To Buy Liminal's Dormant Vaccine Manufacturing Plant In Canada

Ocugen Inc (NASDAQ:OCGN) has signed a non-binding letter of intent to acquire Liminal Biosciences Inc's (NASDAQ:LMNL) manufacturing site in Belleville, Ontario, for an undisclosed amount.

  • The newly acquired site would enable Ocugen to expand its manufacturing and research and development capabilities to support its pipeline, including the manufacture of Covaxin, its COVID-19 vaccine candidate.
  • "We are excited to see Ocugen's plans to repurpose our dormant vaccine manufacturing facility and create vaccine manufacturing capacity in Canada," said Alek Krstajic, Chairman of the Board, Liminal BioSciences.
  • Covaxin was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
  • Related: Ocugen-Bharat Biotech Partnered COVID-19 Booster Covaxin Neutralizes Omicron, Delta Variants.
  • Earlier today, India's drugs regulator has given conditional approval to Covishield and Covaxin for sale in the market. 
  • Market approval, however, does not mean that the vaccines will be available in medical shops. People will have to buy Covishield and Covaxin from hospitals and clinics.
  • Price Action: OCGN shares are down 3.49% at $3.04 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.